Trials / Completed
CompletedNCT01130272
Efficacy, Safety, and Tolerability of JNJ-27018966 (Eluxadoline) in the Treatment of Irritable Bowel Syndrome With Diarrhea
A Randomized, Double-blind, Placebo-controlled, Parallel Group, Dose Ranging, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in the Treatment of Patients With Irritable Bowel Syndrome With Diarrhea
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 807 (actual)
- Sponsor
- Furiex Pharmaceuticals, Inc · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine the efficacy, safety, and tolerability of different doses of JNJ-27018966 (eluxadoline) compared with placebo in the treatment of patients with irritable bowel syndrome with diarrhea (IBS-d).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Eluxadoline | Tablets, orally, twice daily. |
| DRUG | Placebo | Matching placebo oral tablets twice daily. |
Timeline
- Start date
- 2010-04-28
- Primary completion
- 2011-07-14
- Completion
- 2011-07-14
- First posted
- 2010-05-25
- Last updated
- 2019-10-22
- Results posted
- 2019-10-22
Locations
288 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01130272. Inclusion in this directory is not an endorsement.